Epidemiological and Survival Analysis of Primary Intestinal Non-Hodgkin's Lymphoma Patients from SEER Database
Introduction: Gastrointestinal tract is the most common site of extranodal non-Hodgkin's lymphoma (EN-NHL). Most of the data published so far has been on the gastric NHL and very limited data is available on primary intestinal - Non-Hodgkin's Lymphoma (PI-NHL). Here, we are presenting the...
Gespeichert in:
Veröffentlicht in: | Blood 2020-11, Vol.136 (Supplement 1), p.36-36 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Introduction: Gastrointestinal tract is the most common site of extranodal non-Hodgkin's lymphoma (EN-NHL). Most of the data published so far has been on the gastric NHL and very limited data is available on primary intestinal - Non-Hodgkin's Lymphoma (PI-NHL). Here, we are presenting the epidemiological and survival data for PI-NHL from the SEER 21 database.
Methods: Data for all the EN-NHL and Intestinal NHL are collected for the period 2000-2015 from the SEER 21 database based on the WHO ICD-O3 classification. PI-NHL data has been extracted from EN- NHL and intestinal datasets and then cross-matched for accuracy of the desired patient subset selection. A total of 9,290 PI-NHL cases common to both the lists were selected and used for analysis. Patients with incomplete staging and survival data were excluded from the survival analysis. Survival analysis variables include gender (male or female), ethnicity (white or non-white), early age of onset (≤ 50 years), late age of onset (>50 years), location (small or large intestine), the staging of the tumor as early-stage (stage 1 and stage 2) or late-stage tumors (stage 3 and stage 4), and history of prior malignancy (first primary tumor or second/later primary tumor). Survival analysis is done using a cox-proportional hazard regression model.
Results: The percentage of PI-NHL of all the intestinal cancers and extranodal non-Hodgkin’s lymphoma is 1.42% (1.40 - 1.45, 95% CI) and 10.52% (10.32 - 10.72, 95% CI) respectively. The demographic and clinical characteristics of the patients are described in Figure 1. In the survival analysis (Figure 2), the risk of overall mortality is higher in the late-onset cancers (HR - 1.16, 1.08 -1.24, P-value |
---|---|
ISSN: | 0006-4971 1528-0020 |
DOI: | 10.1182/blood-2020-142051 |